Siegfried Holding AG
Siegfried Holding AG is a Swiss life-sciences contract development and manufacturing organization serving pharmaceutical companies worldwide.
Last updated August 26, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Siegfried Holding AG is a Swiss life-sciences company focused on contract development and manufacturing for the pharmaceutical industry. From its headquarters in Zofingen, the company operates an international network of production and development sites in Switzerland, the United States, Malta, China, Germany, France, and Spain. Its activities cover both primary and secondary pharmaceutical manufacturing, allowing customers to outsource several stages of the journey from pharmaceutical research and development to commercial production. The company’s primary manufacturing activities center on active pharmaceutical ingredients, or APIs, as well as related intermediates and controlled substances. These materials are supplied to research-based pharmaceutical companies and can require specialized chemical synthesis, process development, containment, quality systems, and regulatory support. Siegfried also provides secondary manufacturing services for finished dosage forms. These include the development and manufacture of pharmaceutical formulations, tablets and capsules, and sterile liquid products, together with sterile filling capabilities. Siegfried traces its origins to 1873, when pharmacist Samuel Benoni Siegfried and his brother-in-law Johann Wilhelm Dürselen established Siegfried & Dürselen in Zofingen to supply pharmacies. The business gradually developed from a regional pharmaceutical supplier into an international pharmaceutical manufacturing group. An early international step came in 1927, when Siegfried partnered with Gane & Ingram to establish Ganes Chemical Works Inc. in New Jersey. The company marked its centenary by becoming publicly listed on the Basel Stock Exchange in 1973, which later became part of the SIX Swiss Exchange. A significant organizational change took place in 2001, when the holding company was separated into Siegfried and Sidroga. In 2002, Siegfried acquired the United States company Ganes and renamed it Siegfried USA Inc., strengthening its direct presence in the American market. During the following decade, the group increasingly positioned itself as a broad CDMO rather than solely an API manufacturer. In 2012, it entered sterile filling services through the acquisition of Alliance Medical Products in Irvine, California. In 2014, it expanded its sterile liquid manufacturing capabilities by acquiring the contract manufacturing division of Hameln Pharma. The 2015 acquisition of BASF’s contract synthesis business and parts of its API production operations was another major expansion. The acquired activities operated through Siegfried PharmaChemikalien Minden GmbH and included production locations in Minden, Germany, Evionnaz, Switzerland, and Saint-Vulbas, France. In 2018, Siegfried took over Arena Pharmaceuticals GmbH’s finished-product production facility in Zofingen, including its employees and business contracts. This added tablet and capsule manufacturing to the company’s local finished-dose capabilities. Siegfried’s business model is based on long-term technical and manufacturing relationships with pharmaceutical customers. It serves companies that need specialized production capacity, development expertise, quality-controlled supply, or a combination of API and finished-product services. The company’s international footprint supports geographic diversification and access to different manufacturing technologies, while its Swiss origins remain central to its corporate identity. It is an active publicly listed pharmaceutical services group rather than a consumer-facing medicine brand.
History
Siegfried’s history began in 1873 in Zofingen, Switzerland, where pharmacist Samuel Benoni Siegfried and his brother-in-law Johann Wilhelm Dürselen founded Siegfried & Dürselen. The original business supplied pharmacies and established the company’s long-term connection with pharmaceutical products and services. In 1927, Siegfried partnered with Gane & Ingram to establish Ganes Chemical Works Inc. in New Jersey. This created an early foothold in the United States and represented a move beyond the company’s Swiss base. The business later developed toward industrial pharmaceutical and chemical manufacturing, including the production of active pharmaceutical ingredients and related substances. Siegfried became publicly listed on the Basel Stock Exchange in 1973, the company’s centenary year. The Basel exchange subsequently became part of the SIX Swiss Exchange. In 2001, the holding company was divided into Siegfried and Sidroga, creating a clearer separation between the two businesses. The following year, Siegfried acquired Ganes Chemical Works and renamed it Siegfried USA Inc., bringing the American operation more directly into the Siegfried Group. During the 2010s, the company expanded from its established API and chemical manufacturing base into a broader contract development and manufacturing model. In 2012, it acquired Alliance Medical Products in Irvine, California, giving Siegfried an entry into sterile filling. In 2014, the group acquired Hameln Pharma’s contract manufacturing division, adding sterile liquid product manufacturing to its capabilities. In May 2015, Siegfried acquired BASF’s contract synthesis business and parts of BASF’s API production operations. These activities operated as Siegfried PharmaChemikalien Minden GmbH and included production facilities in Minden, Evionnaz, and Saint-Vulbas. The transaction strengthened Siegfried’s chemical synthesis platform and increased its manufacturing presence across Germany, Switzerland, and France. On March 31, 2018, Siegfried took over Arena Pharmaceuticals GmbH’s finished-product production facility in Zofingen. The transaction included the facility’s tablet and capsule operations, employees, and business contracts. It further broadened the company’s secondary manufacturing portfolio and connected the group’s historical Zofingen base with a wider range of finished-dose production services. Today, Siegfried is an international pharmaceutical services group with production sites in Switzerland, the United States, Malta, China, Germany, France, and Spain. Its activities include API development and manufacturing, intermediates and controlled substances, formulation and finished-product development, sterile liquid manufacturing, and sterile filling. The company’s evolution reflects a continuing shift from a traditional pharmaceutical and chemical manufacturer toward a diversified CDMO serving research-based pharmaceutical companies.
- 2018
Zofingen finished-products facility taken over from Arena Pharmaceuticals
[1]Siegfried assumed the Arena Pharmaceuticals GmbH facility producing tablets and capsules, along with employees and business contracts.
- 2015
BASF contract synthesis and API activities acquired
[1]Siegfried acquired BASF’s contract synthesis business and selected API production operations in Germany, Switzerland, and France.
- 2014
Hameln Pharma contract manufacturing division acquired
[1]Siegfried expanded into sterile liquid product manufacturing through the acquisition of Hameln Pharma’s contract manufacturing division.
- 2012
Entry into sterile filling
[1]The acquisition of Alliance Medical Products added sterile filling services to Siegfried’s capabilities.
- 2002
Ganes acquired and renamed Siegfried USA
[1]Siegfried acquired its US company Ganes and renamed it Siegfried USA Inc.
- 2001
Holding company split into Siegfried and Sidroga
[1]The holding structure was separated into Siegfried and Sidroga.
- 1973
Public listing on the Basel Stock Exchange
[1]On its centenary, Siegfried became publicly listed on the Basel Stock Exchange, now part of the SIX Swiss Exchange.
- 1927
Ganes Chemical Works established in New Jersey
[1]Siegfried partnered with Gane & Ingram to create Ganes Chemical Works Inc., establishing an early US presence.
- 1873
Siegfried & Dürselen founded in Zofingen
[1]Samuel Benoni Siegfried and Johann Wilhelm Dürselen established the original pharmacy-supply business in Zofingen, Switzerland.
Products and positioning
A global pharmaceutical contract development and manufacturing organization combining API production, chemical synthesis, formulation development, finished-dose manufacturing, and sterile filling for research-based pharmaceutical companies.
Primary pharmaceutical manufacturing
Active pharmaceutical ingredients
Siegfried develops and manufactures APIs for research-based pharmaceutical companies. The service can encompass process development, chemical synthesis, scale-up, quality-controlled production, and supply of materials for pharmaceutical products. API work is complemented by manufacturing of related intermediates and selected controlled substances.
Chemical pharmaceutical manufacturing
Pharmaceutical intermediates and controlled substances
The company produces chemical intermediates used in pharmaceutical manufacturing and handles selected controlled substances within appropriate manufacturing and compliance frameworks. These activities support customers whose production chains require specialized chemistry before final API manufacture.
Secondary pharmaceutical manufacturing
Finished pharmaceutical formulations
Siegfried provides development and manufacturing services for finished pharmaceutical formulations. Its secondary manufacturing activities extend the company’s role beyond chemical ingredients into dosage-form development, production, packaging-related supply activities, and commercial manufacturing support.
Oral solid dosage manufacturing · 2018
Tablets and capsules
Through the 2018 takeover of the Arena Pharmaceuticals GmbH facility in Zofingen, Siegfried added finished-product production for tablets and capsules. These capabilities support customers seeking outsourced oral solid dosage manufacturing within the company’s broader CDMO platform.
Sterile pharmaceutical manufacturing · 2012
Sterile filling and sterile liquid products
Siegfried offers sterile filling and sterile liquid product manufacturing for pharmaceutical customers. The capability was expanded through the acquisitions of Alliance Medical Products in 2012 and Hameln Pharma’s contract manufacturing division in 2014.
Brand decisions
2018
Takeover of Arena Pharmaceuticals finished-products facilityM&ABackground
Siegfried aimed to strengthen finished-dose manufacturing and connect its Zofingen base with broader pharmaceutical production services.
Action taken
The company took over Arena Pharmaceuticals GmbH’s production facility for tablets and capsules, together with employees and business contracts.
Aftermath
Siegfried increased its secondary manufacturing capacity for finished pharmaceutical products.
2015
Acquisition of BASF contract synthesis and API activitiesM&ABackground
Siegfried pursued scale and additional technical capabilities in pharmaceutical chemistry and contract manufacturing.
Action taken
The company acquired BASF’s contract synthesis business and parts of its API production operations, including sites in Minden, Evionnaz, and Saint-Vulbas.
Aftermath
The transaction expanded Siegfried’s manufacturing footprint and its ability to provide contract synthesis and API services across several European locations.
2014
Acquisition of Hameln Pharma contract manufacturing divisionM&ABackground
The company continued expanding its secondary manufacturing and sterile-product capabilities.
Action taken
Siegfried acquired Hameln Pharma’s contract manufacturing division, including sterile liquid product manufacturing activities.
Aftermath
The acquisition strengthened Siegfried’s position in sterile liquid pharmaceutical production.
2012
Acquisition of Alliance Medical ProductsM&ABackground
Siegfried sought to broaden its service portfolio beyond API and chemical manufacturing into sterile pharmaceutical services.
Action taken
The group acquired Alliance Medical Products, based in Irvine, California, entering the sterile filling segment.
Aftermath
The transaction added sterile filling to Siegfried’s international contract manufacturing platform.
Sources1 sources
Cite this profile: Cite the canonical profile. /brand-wiki/siegfried-holding-ag · Editorial policy · How profiles are compiled